REMTULLA SELLING THYROID DRUG
By Adnews Staff
Remtulla & Associates of Toronto has picked up more business from Knoll Pharma of Markham, Ont. The agency was hired earlier this month in a review to handle advertising for the company's hypothryroidism drug Synthroid. Other agencies in the review were the incumbent, 100% Communications of Montreal, and Knoll's other agency Diamond Strategies of Toronto. Remtulla was given the business because of "their in-depth understanding of industry issues combined with their creative and imaginative program for Synthroid," senior product manager Doug Ross says in a release. Synthroid was owned by Boots Pharmaceuticals of Toronto when it was taken over last spring by Knoll. Subsequently, Knoll decided to call an agency review. When it won Synthroid, Remtulla was already handling advertising for Knoll's cancer pain management drug Dilaudid. Diamond Strategies handles all other drugs, including the popular cardiovascular treatments Rythmol and Isoptin.